



Medical Device Summit - 2017



Omni Parker House Hotel, 60 School Street, Boston, MA, 02108, ÚSA



June 8-9, 2017

25+

MULTIPLE TRACKS













2017 Summit Speakers



Stephen Allan Weitzman Editor in Chief, FDA Information Repository, IRAI



Pat Baird Regulatory Head of Global Software Standards, Philips



Casper E Uldriks
Former Associate Center Director of FDA's CDRH



Rita Hoffman RAC, Managing Partner, Regs & Recall Strategies, Former Branch Chief, Recalls, CDRH, FDA



Nick Sikorski, CISSP Senior Consultant, Deloitte Advisory



Stan Mastrangelo
Technical Committee Member of working group on ISO 31000, ISO 14971, and ICH Q9 Standards, Professor, Center for Applied Health Sciences,
Virginia Tech University



Michael Weickert Strategic & Entrepreneurial Executive, Trail-blazing Leadership in Biotech, Medical Device & Pharmaceutical Business



Roy Wallen President & CEO, Directional Healthcare Advisors, LLC



Rohit Bedi Senior Vice President & Executive Leadership,



Peter Pitts
Chief Regulatory Officer,
Adherent Health, LLC.



Steven Grossman Public Policy & FDA Regulatory Consultant, HPS Group



Brian Shoemaker, Ph.D. Principal Consultant, ShoeBar Associates



Keith Morel, Ph. D. VP, Regulatory Compliance Qserve Group US Inc



Daniel L. Aisen

Quality Assurance. Regulatory Compliance,

Proven Leadership



David Nettelton
Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex
11, HIPAA, Software Validation, and Computer System
Validation



Virginia A. Lang, PhD President & Chief Scientist, Hirlan Inc.



Martyn Gross CEO, Skylit Medical



Daphne Walmer Thought Leader/Expert/Consultant in Medical Device Labeling and Technical Communications



Fletcher Wilson CEO, InterVene, Inc



Roni Cohen
Director of the Microbiology & Chemistry Division,
HYLabs



Scott Philips President Starfish Medicals, StarFish Medicals



Darin Oppenheimer
Director Regulatory, CMC, & Combination Products,

Merck



James Edward Ledlum, Jr Director Corporate Supplier Quality, Hologic, Inc

O2 Cont...

SPEAKERS



Past Summit Speakers from FDA

Ron Brown Branch Chief for Medical Device Recalls, FDA

Bill MacFarland Director, Division of Enforcement B, Office of Compliance, FDA/CDRH

Marisa White Lead Consumer Safety Officer, Division of Bioresearch Monitoring, Office of Compliance, CDRH

Erin Keith Director, Division of Anesthesiology, General Hospital Cisco Vicenty Acting-Branch Chief, Office of Compliance CDRH/FDA

Robin Newman Director, Office of Compliance, Center for Devices and Radiological Health, FDA

Seth D. Carmody Ph.D, Cybersecurity Project Manager, CDRH

> **Neil Mafnas** Assistant Regulator CDRH/FDA

Bakul Patel Associate Center Director for Digital Health at , FDA

Ann Ferriter Director, Division of Analysis and Program Operations CDRH/OC at FDA

Chrissy Cochran Acting Director, Division of Enforcement and Postmarketing Safety at FDA

James Saviola Deputy Director of Regulatory Affairs (Acting), and Director

David Nettelton

Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex

11, HIPAA, Software Validation,

and Computer System Validation

Terri Jollymour

Sr. Director, Operations Readiness

& Convergence,
Johnson & Johnson Corporate

Supply Chain Quality & Compliance Daphne Walmer

Thought Leader/Expert/Consultant in Medical Device Labeling and

Technical Communications

Virginia A. Lang, PhD

President & Chief Scientist.

HirLan, Inc.

Past Summit Speakers

Rick Williams

Partner, Newport Board Group New England Practice, Chairman of Point Care Technology, Board member of.

Amorphex Therapeutics

Geetha Rao Springborne Lifesciences

Haley Lentz

GUDID Submission Subject Matter Expert, Reed Tech

Rohit Bedi Senior Vice President & Executive

Leadership, MetricStream

Eduardo Cervantes

President & CEO. Morf Media Inc

French Caldwell

Chief Evangelist, **MetricStream**

Andrew Pfeifer

Account Executive, REED TECH

Mitch Levinson

Founder, President & CEO, Cerebrotech Medical Systems

Stan Mastrangelo

Technical Committee Member of working group on ISO 31000, ISO 14971, and ICH Q9 Standards, Professor, Center for Applied Health Sciences, Virginia Tech University

Tom Loker

Businessman | Author | Speaker. Startup Consultant and Advisor SYDK.ORG. Contributor to California Political Review

Michael Weickert

Strategic & Entrepreneurial Executive, Trail-blazing Leadership in Biotech, Medical Device & Pharmaceutical

Angela Bazigos

CEO, TouchStone Technologies Silicon valley

Mark Mitchell

SVP Corporate Development at MetricStream & Business head ComplianceOnline

Patrick Rousche Co-Founder and Chief Scientific

Officer, Hemotek Medical, Inc.

Scott Phillips

Starfish Medicals

Joe Franchetti

FDA Regulatory Compliance Specialist. JAF Consulting Inc

Minda Wilson

Affordable Healthcare Review

Darin Oppenheimer

Regulatory Affairs Expert, Global Medical Device Regulations & Licensure Authority, Strategic & Engaging Leader,
Baxter Healthcare Corporation

Kevin Fleming

National Healthcare Managing Director at Newport Board Group

Brian Shoemaker, Ph.D., Principal Consultant,

ShoeBar Associates

Susan W. Neadle

Sr. Director. ssen Pharmaceuticals

Jon Speer Founder and VP of QA/RA, areenliaht.auru

Fletcher Wilson

CEO and Founder

InterVene Inc

Dr. Ron Weissman

Software SIG, Band of Angels

Peter Pitts

Chief Regulatory Officer, Adherent Health, LLC.

Keith Morel, Ph. D.

VP, Regulatory Compliance,

Qserve Group US Inc

Gunjan Sinha Executive Chairman.

MetricStream

Julia Rasooly CEO.

Sponsor

MetricStream

PLATINUM SPONSOR





Media Partners











AGENDA



DAY 01 - JUNE 8, 2017

Note: This program may be subject to alterations and additions

08:00 - 08:30 am	Registration and Breakfast
08:30 - 08:45 am	Welcome Speech Rohit Bedi, Senior Vice President & Executive Leadership, MetricStream
08:45 - 09:10 am	Adequate Directions for Use" in the Age of Al and Watson - Keynote Speech Stephen Allan Weitzman, Editor in Chief at FDA Information Repository, IRAI
99:10 - 09:40 am	FDA Enforcement – Outlook & Implications - Panel Discussion Casper E Uldriks, Former Associate Center Director of FDA's CDRH Rita Hoffman, RAC, Managing Partner, Regs & Recall Strategies, Former Branch Chief, Recalls, CDRH, FDA FDA Invited
09:40 - 10:20 am	Benefit-Risk: Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
10:20 - 10:40 am	Medical Devices under Trump Administration Steven Grossman, Public Policy & FDA Regulatory Consultant, HPS Group
① 10:40 - 11:10 am	Change Management - Managing the Cost of Change Pat Baird, Regulatory Head of Global Software Standards, Philips It is said that the one Constant in life is Change. Whether it is new features, increased reliability, or cost savings, we are constantly asked to make changes to our products and our processes. However, change comes with a cost, and often this cost is either under-estimated or overshadowed by misperceptions by key stakeholders. At this session you will learn how to: Evaluate the cost of change, including both local and hidden costs Evaluate the cost of NOT changing Getting stakeholder buy-in Propagating success
11:10 - 11:25 am	Networking Break
11:25 - 12:05 pm	Post-Market Compliance; No Easy Journey Rita Hoffman, RAC, Managing Partner, Regs & Recall Strategies, Former Branch Chief, Recalls, CDRH, FDA Ineffective or lack of proper Complaint Handing is cited as one of the top violations in a 483 issued at time of inspection by FDA. The number of device companies having their recall classified as a Class 1 (most severe) recall has surged in the past three years. Additionally, product liability and financial risks are staggering when companies fail to properly report and take action when required Ms. Hoffman will explain proper handling of complaints reportable or non-reportable, product complaint handling and documentation filing for both Medical Device Reports (MDR) and eMDR, effective and appropriate communication with the appropriate regulatory agencies in the event of a recalls and how UDI's factor into reporting. She will provide key factors in implementing and maintaining compliance with the regulations from real life experiences from her career in FDA for a correction and removal actions to avoid a recall crisis, including required recordkeeping, expectation from an FDA perspective on achieving regulatory compliance. In addition a brief review of the affect that the new FDA Compliance Guidance's issued in 2016 on post-marketing have had on post-marketing.
12:05 - 12:30 pm	Establishing a Medical Device Security Program Nick Sikorski, CISSP, Senior Consultant, Deloitte Advisory Brief Synopsis of Content: Connected medical devices are playing a transformative and beneficial role in healthcare; however, these devices also pose risks to patient safety and health information security. As innovation continues and the threat landscape evolves, securing medical devices becomes more crucial. Currently, many manufacturers and providers have an ad hoc and device-specific security approach with a lack of a programmatic approach and framework for addressing connected medical device security risks. A mature medical device security program can increase effectiveness and consistency in the execution of security mitigations, including improved collaboration and communication between medical device manufacturers and healthcare providers. This session will focus on industry leading practices related to designing, developing, implementing, and sustaining a mature medical device security program. Learning Objectives: Following this session, the audience will have an enhanced understanding of the below topics:
	✓ The evolution of connected medical devices

12:30 - 01:30 pm

Lunch & Networking

The connected medical device cybersecurity landscape

Industry response to secure connected medical devices

Recent messaging and action of the FDA around medical device cybersecurity

Medical device security program solution for both healthcare providers and medical device manufacturers
 The top risks the industry might face over the next five years, as well as some of the potential industry responses

AGENDA

94:10 - 04:25 pm



① 01:30 - 02:00 pm	Off-label Promotion: Truth or Consequences Casper E Uldriks, Former Associate Center Director of, FDA's CDRH FDA inspects many different kinds of firms. If the FDA regulates your product, they can show up at your lobby and say, "I am here to conduct an inspection." What do you do? What have you done to prepare for an inspection? How do you deal with the investigator, including their personality? The scary part is having to explain the error of your ways to the FDA and above all, managing an administrative action, e.g., Warning Letter or Import Alert, or a legal action, e.g., civil money penalties, seizure, injunction or prosecution. This course will explain what you need to know and what you should do to survive an FDA inspection with the least possible pain.	
	TRACK A - SESSIONS	TRACK B - SESSIONS
O2:00 - 02:25 pm	Sterilization Validation & Biocompatibility for MedTech	Cleaning, Disinfection and Sterilization of Re-usable Medical Devices Roni Cohen, Director of the Microbiology & Chemistry Division, HYLabs
O2:25 - 02:50 pm	Onward to Approval: Documenting Development for Regulatory Compliance Brian Shoemaker, Ph.D., Principal Consultant, ShoeBar Associates	Clinical Evaluation in the EU for Medical Devices - Changing Expectations Keith Morel, Ph.D., VP, Regulatory Compliance, Qserve Group US Inc
O2:50 - 03:20 pm	Medical Device Risk Management 2017 Updates - Workshop Stan Mastrangelo, Technical Committee Member of working group on ISO 31000, ISO 14971, and ICH Q9 Standards, Professor, Center for Applied Health Sciences, Virginia Tech University The last year has been active with changes around the world in Risk Management. Are you familiar with the Compliance Risk requirements of ISO 13485? Is "risk-based thinking" as required by ISO 9001 evident in your organization? Has your organization implemented elements of Enterprise Risk Management based on ISO 31000? And most importantly, the international committee for ISO 14971 is actively working on updating this key standard! Stan will bring you the latest information that will keep you abreast of the recent changes related to managing risk. He will also discuss the vector of future changes. Based on insightful analyses, Stan will present concise key considerations to help you evaluate the currency of your firm's Risk Management program.	
O3:20 - 03:40 pm	Networking Break	
3:40 - 04:10 pm	Best Practices When Interacting with FDA - Panel Discussion FDA Invited	

Closing Mark - Next Day Plan

AGENDA



DAY 02 - JUNE 9, 2017

Note: This program may be subject to alterations and additions

(Section 2015) 08.00 - 08.30 am	Registration and Breakfast	
08:30 - 09:00 am	Cyber Security Risks and Working with Law Enforcement - Keynote Speech FBI Presenting	
O9:00 - 09:30 am	Learning From FDA Warning Letter - How to Stay Out of Trouble? - Panel Discussion Scot Philips, President, Starfish Medicals	
99:30 - 10:00 am	FDA Upcoming Electronic Submission Process - Keynote Speech	
10.00 - 10.25 am	Effective Internal Auditing for Superior Quality Systems Daniel L. Aisen, Quality Assurance. Regulatory Compliance, Proven Leadership	
① 10.25 - 10:55 am	CDRH Office of Compliance Strategic Priorities and Hot Topics in Compliance - Keynote Speech FDA Invited	
10:55 - 11:10 am	Networking Break	
11:10 - 11:40 am	Global Regulatory Landscape (US, EU and APAC): What's on the Horizon? Darin Oppenheimer, Director regulatory, CMC, & Combination Products, Merck	
11:40 - 12:15 pm	Is a Quality Agreement Required for All Suppliers? - Panel Discussion James Edward Ledlum, Jr., Director Corporate Supplier Quality, Hologic, Inc. Casper E Uldriks, Former Associate Center Director of, FDA's CDRH	
12:15 - 12:45 pm	Medical Devices and the Future of Outcomes Centric Peter Pitts, Chief Regulatory Officer, Adherent Health, LLC.	ity
12:45 - 01:45 pm	Lunch & Networking	
	TRACK A - SESSIONS	TRACK B - SESSIONS
① 01:45 - 02:25 pm	TRACK A - SESSIONS FDA Compliance for SaaS/Cloud Environments David Nettelton, Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex 11, HIPAA, Software Validation, and Computer System Validation	TRACK B - SESSIONS Human Factors Compliance: Just Another "Hoop" or Good Business? Virginia A. Lang, PhD., President & Chief Scientist, HirLan, Inc.
① 01:45 - 02:25 pm ② 02:25 - 02:50 pm	FDA Compliance for SaaS/Cloud Environments David Nettelton, Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex 11, HIPAA, Software Validation, and	Human Factors Compliance: Just Another "Hoop" or Good Business? Virginia A. Lang, PhD.,
	FDA Compliance for SaaS/Cloud Environments David Nettelton, Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex 11, HIPAA, Software Validation, and Computer System Validation Digital Health & Medical Devices Roy Wallen, President & CEO, Directional Healthcare Advisors, LLC This presentation addresses the challenges of bringing new medical device technologies to market in the context of market trends that seem to circumvent regulatory requirements. There is a need to balance market opportunity – such as wearable devices that provide useful diagnostic data – with the need to assure safe and effective adoption of those devices. Specific examples of new technologies are presented that appear to avoid standard compliance requirements under the disclaimer that they are "not a medical device". The presentation addresses the issue of how users (i.e., patients) can adopt these devices, how clinicians can use the data in patient treatment, and how regulatory oversight could address the gap	Human Factors Compliance: Just Another "Hoop" or Good Business? Virginia A. Lang, PhD., President & Chief Scientist, HirLan, Inc.
① 02:25 - 02:50 pm	FDA Compliance for SaaS/Cloud Environments David Nettelton, Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex 11, HIPAA, Software Validation, and Computer System Validation Digital Health & Medical Devices Roy Wallen, President & CEO, Directional Healthcare Advisors, LLC This presentation addresses the challenges of bringing new medical device technologies to market in the context of market trends that seem to circumvent regulatory requirements. There is a need to balance market opportunity – such as wearable devices that provide useful diagnostic data – with the need to assure safe and effective adoption of those devices. Specific examples of new technologies are presented that appear to avoid standard compliance requirements under the disclaimer that they are "not a medical device". The presentation addresses the issue of how users (i.e., patients) can adopt these devices, how clinicians can use the data in patient treatment, and how regulatory oversight could address the gap between device use and safety. Developing a Global Strategy for Labelling Daphne Walmer, Thought Leader/Expert/Consultant in Medical Device	Human Factors Compliance: Just Another "Hoop" or Good Business? Virginia A. Lang, PhD., President & Chief Scientist, HirLan, Inc. FDA Quality Metrics Update Early R&D Best Practices from Concept to First in Human Studies
© 02:25 - 02:50 pm © 02:50 - 03:10 pm	FDA Compliance for SaaS/Cloud Environments David Nettelton, Industry Leader, Author, and Teacher for 21 CFR Part 11, Annex 11, HIPAA, Software Validation, and Computer System Validation Digital Health & Medical Devices Roy Wallen, President & CEO, Directional Healthcare Advisors, LLC This presentation addresses the challenges of bringing new medical device technologies to market in the context of market trends that seem to circumvent regulatory requirements. There is a need to balance market opportunity – such as wearable devices that provide useful diagnostic data – with the need to assure safe and effective adoption of those devices. Specific examples of new technologies are presented that appear to avoid standard compliance requirements under the disclaimer that they are "not a medical device". The presentation addresses the issue of how users (i.e., patients) can adopt these devices, how clinicians can use the data in patient treatment, and how regulatory oversight could address the gap between device use and safety. Developing a Global Strategy for Labelling Daphne Walmer, Thought Leader/Expert/Consultant in Medical Device Labeling and Technical Communications	Human Factors Compliance: Just Another "Hoop" or Good Business? Virginia A. Lang, PhD., President & Chief Scientist, HirLan, Inc. FDA Quality Metrics Update Early R&D Best Practices from Concept to First in Human Studies Fletcher Wilson, CEO, InterVene, Inc.



.....Registration Form

Registration Information:

- » Register Online. Use your American Express, Visa or MasterCard.
- » Get your group to attend the summit at a discounted price call +1-888-717-2436.
- » Call +1-888-717-2436 or Fax your PO: +1-650-565-8542
- » Pay your check to (payee name) "MetricStream Inc" our parent company and mail the check to: ComplianceOnline (MetricStream, Inc), 2479 East Bayshore Road, Suite 200, Palo Alto, CA 94303
- » Please fill this form with attendee details and payment details and fax it to +1-650-565-8542

Terms & Conditions:

Your Registration for the summit is subject to following terms and conditions. If you need any clarification before registering for this summit please call us at +1-888-717-2436 or email us at customercare@complianceonline.com

Cancellations and Substitutions:

Written cancellations through fax or email (from the person who has registered for this conference) received at least 10 calendar days prior to the start date of the event will receive a refund - less a \$300 administration fee. No cancellations will be accepted - nor refunds issued - within 10 calendar days from the start date of the event. On request by email or fax (before the summit) a credit for the amount paid minus administration fees (\$300) will be transferred to any future ComplianceOnline event and a credit note will be issued. Substitutions may be made at any time. No-shows will be charged the full amount. We discourage onsite registrations, however if you wish to register onsite payment to happen through credit card immediately or check to be submitted onsite. Conference material will be given on the spot if it is available after distributing to other attendees. In case it is not available we will send the material after the conference is over. In the event ComplianceOnline cancels the summit, ComplianceOnline is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.

Date & Location:	
Attendee 1 : Name	Email
Attendee 2 : Name	Email
Attendee 3 : Name	Email
Attendee 4 : Name	Email
Attendee 5 : Name	Email
Attendee 6 : Name	Email
Attendee 7 : Name	Email
Attendee 8 : Name	Email
Company Information	Payment Options
Organization	 Check enclosed, payable in U.S. funds to (Payee Name) (MetricStream, Inc.)
Address	☐ Charge to: ☐ Visa ☐ MasterCard ☐ American Express
City	Credit card no
PhoneFax	Signature
Compliance nine The Largest GRC Advisory Network MetricStream	Bill me/my company \$Purchase order #(Payment is required by the date of the conference.) Please fill this form with attendee details and payment details and fax it to +1-650-565-8542